TONSL antisense RNA 1 (TONSL-AS1)

TONSL antisense RNA 1 (TONSL-AS1) is a long non-coding RNA (lncRNA) transcribed from the antisense strand of the TONSL gene. It has emerged as a significant player in various biological processes, particularly in the context of human diseases, most notably cancer. TONSL-AS1 frequently acts as an oncogene in multiple cancer types, including hepatocellular carcinoma, gastric cancer, non-small cell lung cancer, and colorectal cancer, where its upregulation is associated with tumor progression, metastasis, and poor patient prognosis. Its molecular mechanisms involve regulating the expression of its sense gene TONSL and acting as a competing endogenous RNA (ceRNA) to sponge specific microRNAs (miRNAs), thereby de-repressing their target messenger RNAs. Through these actions, TONSL-AS1 influences critical cellular functions such as cell proliferation, migration, invasion, and apoptosis. Its consistent dysregulation in various malignancies makes TONSL-AS1 a promising diagnostic, prognostic biomarker, and a potential therapeutic target, although drug development is still in early stages.

Other names

LINC01057

TONSL-AS1 functions primarily as a long non-coding RNA that regulates gene expression. Its main mechanisms include acting as an antisense transcript to the TONSL gene, thereby modulating TONSL's expression. Additionally, it frequently acts as a competing endogenous RNA (ceRNA), sequestering specific microRNAs (miRNAs) to relieve their suppressive effects on target messenger RNAs (mRNAs). This de-repression of target mRNAs contributes to various cellular processes, including cell cycle progression, proliferation, epithelial-mesenchymal transition (EMT), and inhibition of apoptosis, particularly in cancer.